Fc γ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder
Joint Authors
Reinke, Petra
Riess, Hanno
Zimmermann, Heiner
Weiland, Theresa
Nourse, Jamie P.
Gandhi, Maher K.
Neuhaus, Ruth
Karbasiyan, Mohsen
Gärtner, Barbara
Anagnostopoulos, Ioannis
Trappe, Ralf U.
Oertel, Stephan
Source
Journal of Immunology Research
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-02-10
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy.
Previous reports had indicated that the lower affinity F allele affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and is linked to inferior outcome of rituximab monotherapy in B cell malignancies.
25 patients with PTLD after solid organ transplantation were included in this analysis.
They had received 4 weekly doses of rituximab as part of two clinical trials, which had a rituximab monotherapy induction regimen in common.
16/25 patients received further treatment with CHOP-21 after rituximab monotherapy (PTLD-1, NCT01458548).
The FCGR3A status was correlated to the response after 4 cycles of rituximab monotherapy.
Response to rituximab monotherapy was not affected by F carrier status.
This is in contrast to previous findings in B cell malignancies where investigators found a predictive impact of FCGR3A status on outcome to rituximab monotherapy.
One explanation for this finding could be that ADCC is impaired in transplant recipients receiving immunosuppression.
These results suggest that carrying a FCRG3A F allele does not negatively affect rituximab therapy in immunosuppressed patients.
American Psychological Association (APA)
Zimmermann, Heiner& Weiland, Theresa& Nourse, Jamie P.& Gandhi, Maher K.& Reinke, Petra& Neuhaus, Ruth…[et al.]. 2014. Fc γ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder. Journal of Immunology Research،Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1040807
Modern Language Association (MLA)
Zimmermann, Heiner…[et al.]. Fc γ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder. Journal of Immunology Research No. 2014 (2014), pp.1-6.
https://search.emarefa.net/detail/BIM-1040807
American Medical Association (AMA)
Zimmermann, Heiner& Weiland, Theresa& Nourse, Jamie P.& Gandhi, Maher K.& Reinke, Petra& Neuhaus, Ruth…[et al.]. Fc γ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder. Journal of Immunology Research. 2014. Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1040807
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1040807